OBJECTIVE: PR (PRDI-BF1 and RIZ) domain proteins (PRDM) are a subfamily of the kruppel-like zinc finger gene products and play key roles during cell differentiation and malignant transformation. PRDM5 (PR domain containing 5 PFM2) is a new PR-domain-containing gene. The purpose of the present study was to examine the expression of PRDM5 and evaluate its carcinogenesis in cervical cancer. The relationship between DNA methylation and transcriptional silencing of PRDM5 was investigated in cervical cancer. METHODS: PRDM5 expression was examined in cervical cancer cell lines and cervical tissues (12 normal and 42 cancerous) by using RT polymerase chain reaction (PCR). Methylation status of the PRDM5 promoter was studied using methylation-specific PCR (MSP). RESULTS: PRDM5 expression is reduced or lost in cervical cancers, compared with normal cervical tissues (P < 0.05). The current study results also showed that loss of PRDM5 is mediated by aberrant cytosine methylation of the PRDM5 promoter. There were 40.5% of carcinomas methylated, while none of normal tissues were methylated. PRDM5 mRNA expression was significantly higher (P = 0.000) in unmethylated (0.2634 ± 0.0674, mean ± SD), compared with methylated tissues (0.1007 ± 0.0993, mean ± SD). Last, treatment with a DNA methyltransferase inhibitor led to reactivation of PRDM5 expression in cell lines that had negligible PRDM5 expression at baseline. CONCLUSIONS: Reduced expression of PRDM5 may play an important role in the pathogenesis and/or development of cervical cancer, and is considered to be caused in part by aberrant DNA methylation.
OBJECTIVE: PR (PRDI-BF1 and RIZ) domain proteins (PRDM) are a subfamily of the kruppel-like zinc finger gene products and play key roles during cell differentiation and malignant transformation. PRDM5 (PR domain containing 5 PFM2) is a new PR-domain-containing gene. The purpose of the present study was to examine the expression of PRDM5 and evaluate its carcinogenesis in cervical cancer. The relationship between DNA methylation and transcriptional silencing of PRDM5 was investigated in cervical cancer. METHODS:PRDM5 expression was examined in cervical cancer cell lines and cervical tissues (12 normal and 42 cancerous) by using RT polymerase chain reaction (PCR). Methylation status of the PRDM5 promoter was studied using methylation-specific PCR (MSP). RESULTS:PRDM5 expression is reduced or lost in cervical cancers, compared with normal cervical tissues (P < 0.05). The current study results also showed that loss of PRDM5 is mediated by aberrant cytosine methylation of the PRDM5 promoter. There were 40.5% of carcinomas methylated, while none of normal tissues were methylated. PRDM5 mRNA expression was significantly higher (P = 0.000) in unmethylated (0.2634 ± 0.0674, mean ± SD), compared with methylated tissues (0.1007 ± 0.0993, mean ± SD). Last, treatment with a DNA methyltransferase inhibitor led to reactivation of PRDM5 expression in cell lines that had negligible PRDM5 expression at baseline. CONCLUSIONS: Reduced expression of PRDM5 may play an important role in the pathogenesis and/or development of cervical cancer, and is considered to be caused in part by aberrant DNA methylation.
Authors: Mei Y Yu; Joanna H M Tong; Paul K S Chan; Tin L Lee; Michael W Y Chan; Anthony W H Chan; Kwok W Lo; Kai F To Journal: Int J Cancer Date: 2003-06-10 Impact factor: 7.396
Authors: Hoenil Jo; Sokbom Kang; Jae W Kim; Gyeong H Kang; Noh H Park; Yong S Song; Sang Y Park; Soon B Kang; Hyo P Lee Journal: J Obstet Gynaecol Res Date: 2007-06 Impact factor: 1.730
Authors: Laura Pasqualucci; Mara Compagno; Jane Houldsworth; Stefano Monti; Adina Grunn; Subhadra V Nandula; Jon C Aster; Vundavally V Murty; Margaret A Shipp; Riccardo Dalla-Favera Journal: J Exp Med Date: 2006-02-20 Impact factor: 14.307
Authors: Louise F Porter; Giorgio G Galli; Sally Williamson; Julian Selley; David Knight; Nursel Elcioglu; Ali Aydin; Mustafa Elcioglu; Hanka Venselaar; Anders H Lund; Richard Bonshek; Graeme C Black; Forbes D Manson Journal: Hum Mol Genet Date: 2015-09-22 Impact factor: 6.150
Authors: Catherine E Bond; Mark L Bettington; Sally-Ann Pearson; Diane M McKeone; Barbara A Leggett; Vicki L J Whitehall Journal: BMC Cancer Date: 2015-01-23 Impact factor: 4.430